Mizuho Securities Sticks to Its Buy Rating for Aerie Pharma (AERI)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $77. The company’s shares closed yesterday at $49.25.

Yang said:

“We are including weekly IQVIA Scripts for Rhopressa below. For the week ended 03/15/2019, Rhopressa TRx decreased -1.4% to 5,921 from 6,007 the prior week; and Rhopressa NRx increased +0.7% to 2,556 from 2,539 the prior week. We provide scripts data for informative purposes only. We believe investors should focus on longer-term demand trends vs. weekly fluctuations. For investors to keep in mind: IQVIA reporting has changed going back to the week ending 01/06/17. Prior to the reporting change, volumes reflected all volumes dispensed, even if not accepted by patients. The new reporting only reflects prescriptions accepted by patients. We compared the updated IQVIA data for Rhopressa since launch to historical data. We note that the weekly decline in TRx ranges from -10% to -16%, with an average of -13%.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 19.3% and a 53.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $80 average price target, which is a 62.4% upside from current levels. In a report issued on March 13, Oppenheimer also maintained a Buy rating on the stock with a $64 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $74.75 and a one-year low of $32.18. Currently, Aerie Pharma has an average volume of 679.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105.